Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
31
CATX Quote, Financials, Valuation and Earnings
Last price:
$3.23
Seasonality move
:
41.25%
Day range:
$3.09 - $3.28
52-week range:
$2.70 - $19.05
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.55x
P/B ratio:
0.67x
Volume:
502.8K
Avg. volume:
2.3M
1-year change:
-14.47%
Market cap:
$219.7M
Revenue:
--
EPS (TTM):
-$1.46
Analysts' Opinion
-
Consensus RatingPerspective Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.15, Perspective Therapeutics has an estimated upside of 396.92% from its current price of $3.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing -84.62% downside risk from its current price of $3.25.
Fair Value
-
According to the consensus of 9 analysts, Perspective Therapeutics has 396.92% upside to fair value with a price target of $16.15 per share.
CATX vs. S&P 500
-
Over the past 5 trading days, Perspective Therapeutics has overperformed the S&P 500 by 2.83% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Perspective Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Perspective Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Perspective Therapeutics reported revenues of --.
Earnings Growth
-
Perspective Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Perspective Therapeutics reported earnings per share of -$0.21.
Enterprise value:
-46.5M
EV / Invested capital:
--
Price / LTM sales:
17.55x
EV / EBIT:
--
EV / Revenue:
-4.67x
PEG ratio (5yr expected):
-0.27x
EV / Free cash flow:
1.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $9.9M | $7M | -- | $1.9M | -- | |
| Gross Profit | $4M | -- | -- | -- | -- | |
| Operating Income | -$9.3M | -$33.5M | -$57.6M | -$9.8M | -$18.6M | |
| EBITDA | -$9.1M | -$31.9M | -$47.8M | -$9.3M | -$14.4M | |
| Diluted EPS | -$0.60 | -$1.07 | -$1.46 | -$0.37 | -$0.21 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.7M | $65M | $57.5M | $21.7M | $270.2M | |
| Total Assets | $8M | $68.7M | $62.5M | $110.5M | $391.2M | |
| Current Liabilities | $1.5M | $1.8M | $4M | $8.1M | $28.1M | |
| Total Liabilities | $2.9M | $3M | $4.8M | $11.7M | $62.7M | |
| Total Equity | $5.1M | $65.8M | $57.7M | $98.8M | $328.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.4M | -$29.7M | -$696K | -$10.1M | $3.4M | |
| Cash From Investing | -$35.4M | -$10.7M | -$80.4M | -$227K | -$29.7M | |
| Cash From Financing | $84K | $461K | $289.4M | $1K | $628K | |
| Free Cash Flow | -$7.7M | -$30.7M | -$40.6M | -$10.3M | -$26.3M | |
CATX
Sector
Market Cap
$219.7M
$46.1M
Price % of 52-Week High
17.06%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-14.47%
-30.52%
Beta (5-Year)
1.129
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$3.14
200-day SMA
Sell
Level
$12.12
Bollinger Bands (100)
Sell
Level
6.4 - 14.96
Chaikin Money Flow
Sell
Level
-322.7M
20-day SMA
Sell
Level
$3.58
Relative Strength Index (RSI14)
Sell
Level
28.01
ADX Line
Sell
Level
54.39
Williams %R
Neutral
Level
-61.5385
50-day SMA
Sell
Level
$7.60
MACD (12, 26)
Sell
Level
-1.22
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
531.6M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Stock Forecast FAQ
In the current month, CATX has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CATX average analyst price target in the past 3 months is $16.15.
-
Where Will Perspective Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Perspective Therapeutics share price will rise to $16.15 per share over the next 12 months.
-
What Do Analysts Say About Perspective Therapeutics?
Analysts are divided on their view about Perspective Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Perspective Therapeutics is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Perspective Therapeutics's Price Target?
The price target for Perspective Therapeutics over the next 1-year time period is forecast to be $16.15 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CATX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Perspective Therapeutics is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CATX?
You can purchase shares of Perspective Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Perspective Therapeutics shares.
-
What Is The Perspective Therapeutics Share Price Today?
Perspective Therapeutics was last trading at $3.23 per share. This represents the most recent stock quote for Perspective Therapeutics. Yesterday, Perspective Therapeutics closed at $3.25 per share.
-
How To Buy Perspective Therapeutics Stock Online?
In order to purchase Perspective Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
